Page All:
Page 1
EvaluatePharma® Launches Tracking Drugs@FDA
LONDON, October 22, 2012 /PRNewswire/ --
Tracking Drugs@FDA and Orange Book Patent Data Provides Unrivaled Analysis of FDA
Market Intelligence
EvaluatePharma [http://www.evaluatepharma.com ], the premier source for life science
sector analysis and consensus forecasts, today launched a new service enhancement,
Tracking Drugs@FDA, which gives clients access to the entire universe of approved FDA
drugs and the related FDA document library as well as FDA Orange Book patent data - all
fully integrated into the industry-leading EvaluatePharma platform and analytical tools.
"Through our proprietary software platform and meticulous data standardization,
Tracking Drugs@FDA finally unlocks the value of the massive FDA approval & patent
datasets, whatever your area of interest might be," said Anthony Raeside, Head of
Research, EvaluatePharma.
Tracking Drugs@FDA provides unmatched regulatory approval analysis such as the ability
to:
- Find in-depth information on FDA approved brand names, generic drugs and
therapeutic biological products, including orphan drugs
- Track FDA approvals by company, pharma class, therapeutics area, indication
and formulation
- Review labels for approved drug products
- Track generics landscape against a brand name drug product using a unique
Generics Availability analysis field to detail active approvals (ANDA) and tentative
approvals
- Find therapeutically equivalent drug products for a brand name or generic
- Analyze the entire generic landscape by EvaluatePharma's proprietary generic
equivalent field: active ingredient, formulation and dosage
- Access Orange Book data to track latest product patent and exclusivity
- Find products approved by company
Tracking Drugs@FDA also features the standard capabilities provided by
EvaluatePharma's proven platform including the ability to search and drill-down in fine
detail, create and export highly customized reports and manage and receive new
deeper-level data alerts via email.
Tracking Drugs@FDA is included in the latest version of the EvaluatePharma service,
which covers the biotechnology and pharmaceutical sector. Visit our website
[http://evaluatepharma.com/OurProducts_TrackingDrugsatFDA.aspx ] to learn more about this
enhancement and how you can gain access to intelligence you can act on.
About EvaluatePharma
Since 1996, EvaluatePharma [http://www.evaluatepharma.com ] has been the premier
source for life science sector analysis, delivering exclusive, trusted commercial insight
into industry performance through its proprietary platform. EvaluatePharma
[http://www.evaluatepharma.com ] is staffed by a team of over 85 dedicated healthcare
analysts employing rigorous methodologies to collate, organize and deliver the
most-up-to-date commercial performance data available. An award winning editorial team of
journalists writing under the EP Vantage(R) name support EvaluatePharma's analysis. The
company's newest service offering, EvaluateMedTech [http://www.evaluatemedtech.com ](TM),
provides the first consensus view of the medical device and diagnostic industry. The
EvaluatePharma services enable the life science community to make sound business decisions
about value and opportunity. For more information please visit
http://www.EvaluatePharma.com.
Media Contacts:
EvaluatePharma
Christine Lindgren
+1-617-866-3906
christinel@EvaluatePharma.com
Chempetitive Group
Erik Clausen
+1-858-457-2436
eclausen@chempetitive.com
EvaluatePharma Ltd
EvaluatePharma® Launches Tracking Drugs@FDA
LONDON, October 22, 2012 /PRNewswire/ --
Tracking Drugs@FDA and Orange Book Patent Data Provides Unrivaled Analysis of FDA
Market Intelligence
EvaluatePharma [http://www.evaluatepharma.com ], the premier source for life science
sector analysis and consensus forecasts, today launched a new service enhancement,
Tracking Drugs@FDA, which gives clients access to the entire universe of approved FDA
drugs and the related FDA document library as well as FDA Orange Book patent data - all
fully integrated into the industry-leading EvaluatePharma platform and analytical tools.
"Through our proprietary software platform and meticulous data standardization,
Tracking Drugs@FDA finally unlocks the value of the massive FDA approval & patent
datasets, whatever your area of interest might be," said Anthony Raeside, Head of
Research, EvaluatePharma.
Tracking Drugs@FDA provides unmatched regulatory approval analysis such as the ability
to:
- Find in-depth information on FDA approved brand names, generic drugs and
therapeutic biological products, including orphan drugs
- Track FDA approvals by company, pharma class, therapeutics area, indication
and formulation
- Review labels for approved drug products
- Track generics landscape against a brand name drug product using a unique
Generics Availability analysis field to detail active approvals (ANDA) and tentative
approvals
- Find therapeutically equivalent drug products for a brand name or generic
- Analyze the entire generic landscape by EvaluatePharma's proprietary generic
equivalent field: active ingredient, formulation and dosage
- Access Orange Book data to track latest product patent and exclusivity
- Find products approved by company
Tracking Drugs@FDA also features the standard capabilities provided by
EvaluatePharma's proven platform including the ability to search and drill-down in fine
detail, create and export highly customized reports and manage and receive new
deeper-level data alerts via email.
Tracking Drugs@FDA is included in the latest version of the EvaluatePharma service,
which covers the biotechnology and pharmaceutical sector. Visit our website
[http://evaluatepharma.com/OurProducts_TrackingDrugsatFDA.aspx ] to learn more about this
enhancement and how you can gain access to intelligence you can act on.
About EvaluatePharma
Since 1996, EvaluatePharma [http://www.evaluatepharma.com ] has been the premier
source for life science sector analysis, delivering exclusive, trusted commercial insight
into industry performance through its proprietary platform. EvaluatePharma
[http://www.evaluatepharma.com ] is staffed by a team of over 85 dedicated healthcare
analysts employing rigorous methodologies to collate, organize and deliver the
most-up-to-date commercial performance data available. An award winning editorial team of
journalists writing under the EP Vantage(R) name support EvaluatePharma's analysis. The
company's newest service offering, EvaluateMedTech [http://www.evaluatemedtech.com ](TM),
provides the first consensus view of the medical device and diagnostic industry. The
EvaluatePharma services enable the life science community to make sound business decisions
about value and opportunity. For more information please visit
http://www.EvaluatePharma.com.
Media Contacts:
EvaluatePharma
Christine Lindgren
+1-617-866-3906
christinel@EvaluatePharma.com
Chempetitive Group
Erik Clausen
+1-858-457-2436
eclausen@chempetitive.com
EvaluatePharma Ltd